What Is Wegovy and How Does It Work?
Wegovy is semaglutide, a GLP-1 receptor agonist injected weekly under the skin. It mimics a gut hormone that slows stomach emptying, reduces appetite, and signals fullness to the brain, leading to 15-20% average body weight loss in trials over 68 weeks.[1][2]
How Wegovy Compares to Older Weight Loss Drugs Like Phentermine or Qsymia
Phentermine, an older stimulant, suppresses appetite short-term (up to 12 weeks) with 5-10% weight loss but carries addiction risks and rebound weight gain. Qsymia combines phentermine with topiramate for similar modest results (8-10% loss). Wegovy outperforms these, sustaining greater loss without stimulants, though it's pricier and requires ongoing use.[1][3]
Wegovy vs. Ozempic and Other Semaglutide Versions
Wegovy uses higher-dose semaglutide (2.4 mg weekly) approved solely for weight loss, while Ozempic (up to 2 mg) targets diabetes with off-label weight loss use (10-15% loss). Mounjaro (tirzepatide) adds GIP agonism for potentially superior 20-25% loss but faces supply issues. All share GI side effects, but Wegovy's dosing is optimized for obesity.[2][4]
Wegovy Compared to Surgical Options Like Gastric Bypass
Bariatric surgery like gastric bypass yields 20-30% sustained loss but involves risks like infection or nutrient deficiencies, costing $20,000+ out-of-pocket. Wegovy offers non-invasive results closer to surgery (15-20% loss) with reversibility—weight returns if stopped—but requires lifestyle changes for maintenance.[1][5]
Common Side Effects and Why Patients Switch Treatments
Wegovy causes nausea (44%), diarrhea (30%), and vomiting (24%) early on, often improving over time; rare pancreatitis or thyroid risks exist.[2] Patients report better tolerability than tirzepatide's stronger GI effects but fatigue muscle loss concerns versus surgery's quicker results. Dropout rates hit 7-16% in trials due to side effects.[1][4]
Cost, Coverage, and Who Can't Use Wegovy
Wegovy lists at $1,350/month without insurance; copays drop to $25 with coverage for eligible obesity patients (BMI 30+ or 27+ with conditions). Medicare covers it post-2024 updates, unlike many prior drugs. Not for type 1 diabetes or thyroid cancer history; kids 12+ approved.[3][6]
When Does Wegovy's Patent Expire and What About Biosimilars?
Novo Nordisk holds patents on semaglutide until 2032 in the US, with formulation patents to 2034. Challenges from competitors like Hims & Hers could accelerate generics, but no biosimilars yet. This delays cheaper options versus off-patent phentermine.[7]
[1] NEJM: Semaglutide 2.4 mg trial (2021). https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
[2] FDA Wegovy Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf
[3] GoodRx pricing comparison. https://www.goodrx.com/wegovy
[4] JAMA: Tirzepatide vs semaglutide (2023). https://jamanetwork.com/journals/jama/fullarticle/2802486
[5] NIH bariatric outcomes. https://www.niddk.nih.gov/health-information/weight-management/bariatric-surgery
[6] CMS Medicare coverage (2024). https://www.cms.gov/newsroom/fact-sheets/medicare-advantage-coverage-obesity-drugs
[7] DrugPatentWatch: Semaglutide patents. https://www.drugpatentwatch.com/p/tradename/WEGOVY